


Delphic

SCIENTIFIC EXPERTISE

pharmacology pharmacogenetics virology

DMET PANEL
GENOTYPING
NUCLEIC ACID EXTRACTION
VALIDATED METHODS
CUSTOM PHARMACOGENETICS / RESEQUENCING



Please contact us to discuss your study requirements and to learn more about our range of assays and expertise

Clinically relevant SNPs

HLA-B*5701
UGT*28
CYP2B6*4
CYP2D6
CYP3A4
HSP70
DRB070101
DRB4*0103102 NUL
DQB1*0303
DQB1*0101

Phase I enzymes Cytochrome P450

CYP1A1
CYP1A2
CYP2A6
CYP2B6
CYP2C9
CYP2C19
CYP2D6
CYP2E1
CYP3A4
CYP3A5



Phase II enzymes

NAT-1
NAT-2
GSTM1
GSTT
SULT1A1
SULT1A2

CONTACT

Jon Ventham
Sales Director
+44.20.7499.0777
+44.7966.125018
jon.ventham@delphicdiagnostics.com
www.delphicdiagnostics.com

- BIO-EQUIVALENCE STUDIES
- VALIDATED METHODS
- DRUG-DRUG INTERACTION STUDIES
- DOSE ESCALATING STUDIES
- CLINICAL INTERPRETATION / BIOINFORMATICS



Delphic develops custom methodology for your compound(s), transfers your existing methods to our dedicated pharmacology laboratory and/or develops your current methodology.

Please contact us to discuss your study requirements and to learn more about our range of assays and expertise

Non-proprietary compounds clinically validated

Atazanavir	Maraviroc
Amprenavir	Nelfinavir
Indinavir	Nevirapine
Darunavir	Saquinavir
Efavirenz	Lopinavir
Etravirine	Raltegravir
Ribavirin	Tenofovir
Ritonavir	Tipranavir


Non-proprietary compounds include

Abacavir	Lamivudine
Acetaminophen	Losartan
Adefovir	Metoprolol
Caffeine	Midazolam
Chlorzoxazone	Omeprazole
Dapsone	Pegylated interferon
Debrisoquinine	Quinine
Dextromethorphan	Rosiglitazone
Emtricitabine	Tolbutamide
Entecavir	Tylenol
Interferon	Warfarin

CONTACT

Jon Ventham
Sales Director
+44.20.7499.0777
+44.7966.125018
jon.ventham@delphicdiagnostics.com
www.delphicdiagnostics.com

HIV-1
HEPATITIS B
HEPATITIS C
HPV



Delphic has unique experience as a specialist laboratory for HIV and hepatitis. We supply diagnostic testing to the healthcare sector providing rapid turnaround times and results that incorporate clinical algorithms. We are now applying this expertise to all drug development and clinical trial stages including real-time and adaptive trials.

Please contact us to discuss your study requirements and to learn more about our range of assays and expertise

Pharmacology

Therapeutic drug monitoring

(incorporating clinical algorithm-driven reporting)

Atazanavir	Maraviroc
Amprenavir	Nelfinavir
Indinavir	Nevirapine
Darunavir	Saquinavir
Efavirenz	Lopinavir
Etravirine	Raltegravir
Ribavirin	Tenofovir
Ritonavir	Tipranavir

Pharmacogenetics

HLA-B*5701
UGT*28
CYP2B6*4
CYP2D6
CYP3A4
HSP70
DRB070101
DRB4*0103102 NUL
DQB1*0303
DQB1*0101

Virology

Viral load
Genotyping
Viral resistance testing
Tropism
Flow cytometry
CD4/CD8

CONTACT

Jon Ventham
Sales Director
+44.20.7499.0777
+44.7966.125018
jon.ventham@delphicdiagnostics.com
www.delphicdiagnostics.com

SCIENTIFIC DIRECTOR

DAVID BACK

PROFESSOR OF PHARMACOLOGY
UNIVERSITY OF LIVERPOOL

David Back is a Professor of Pharmacology at the University of Liverpool and established the Liverpool HIV Pharmacology Group (LHPG) in 1987. The Liverpool Group have been at the forefront of pharmacological research of antiretroviral drugs. Currently there are numerous ongoing pharmacokinetic (TDM, IQ, drug-drug interaction, pharmacological mechanisms of resistance) and pharmacogenomic (phenotype-genotype) studies involving local, national and international collaborations. It also runs the highly successful web site www.hiv-druginteractions.org and, with colleagues in Switzerland, Canada and Australia, the website www.hiv-pharmacogenomics.org. David has authored or co-authored more than 350 publications. He is a former Editor-in-Chief of the British Journal of Clinical Pharmacology and is currently on the Editorial Board of JAIDS and Therapeutic Drug Monitoring.

CLINICAL DIRECTOR

SAYE KHOO MB MD FRCP DTM&H

READER IN PHARMACOLOGY, UNIVERSITY OF LIVERPOOL
HON CONSULTANT PHYSICIAN IN INFECTIOUS DISEASES,
ROYAL LIVERPOOL UNIVERSITY HOSPITAL

Dr Khoo is lead HIV Clinician for the Royal Liverpool & Broadgreen Hospitals NHS Trust and Chair of the Mersey, Cheshire & N Wales HIV Managed Care Network. He is also a board member of the Mersey & Cheshire Sexual Health Network, and the Regional Sexual Health Task Group for NW England. He currently serves on the British HIV Association Treatment Guidelines Committee, the joint British HIV Association/British Infection Society Opportunistic Infections Guidelines Committee, and the British Thoracic Society Guidelines Joint Tuberculosis committee advising on the prevention and management of TB in patients with renal impairment. Other current / recent activities are: Pharmacology Steering Group, PENTA (EU / MRC Pediatric HIV Clinical Trials Network), Editor, Journal of Antimicrobial Chemotherapy (2003 - 2007), HEFCE Clinical Senior Lectureship Award Referees Panel. Research interests centre on the pharmacology of HIV treatment failure. This includes the role of therapeutic drug monitoring, population pharmacokinetic modelling, investigation of drug interactions, molecular characterisation of drug metabolism and disposition pathways and the role of host genetic variability in influencing drug exposure and response. There is also a focus on HIV therapy in resource-poor settings, and the pharmacology of anti-tuberculous therapy.

R&D DIRECTOR

C A DALE SMITH BSc MSc PhD

RESEARCH AND DEVELOPMENT DIRECTOR
DELPHIC DIAGNOSTICS

Dr Smith has over 24 years of experience in molecular biology, virology, cancer research and the genetics of human disease. His interests have a particular emphasis on genetic predisposition to disease and the development of diagnostic tests for genetic variation in populations. On gaining a PhD from the University of Manchester, UK, Dr Smith spent six years in government research in the United States including five years as a Fogarty International Fellow at the National Institutes of Health. Returning to the UK in 1990, he developed an interest in genetic variation, firstly as a senior scientist with the Imperial Cancer Research Fund in Edinburgh, then as an independent investigator at the University of Edinburgh. Since 1998, Dr Smith has been developing commercial nucleic acid extraction and pharmacogenetic genotyping services, firstly as CEO at Genovar Bioscience, and currently as Laboratory Director of Delphic Laboratories (Kent) Ltd and as R&D Director of Delphic Diagnostics Ltd.

MEDICAL DIRECTOR

ANTON POZNIAK MD FRCP

CONSULTANT PHYSICIAN / HONORARY SENIOR LECTURER
CHELSEA & WESTMINSTER HOSPITAL IMPERIAL COLLEGE
LONDON

Dr Anton Pozniak studied medicine at the University of Bristol UK and qualified in 1979. He started caring for patients with HIV in 1983 at the Middlesex Hospital, London UK. He went to Zimbabwe as a Consultant Physician in 1989 where he researched for his doctorate in TB/HIV and then moved back to the UK in 1991. He ran the HIV unit at King's College, London, before moving to his current position as Consultant Physician/Senior Lecturer at the Chelsea and Westminster Hospital in 1998 where he is the Executive Director of HIV research. He became a fellow of the Royal College of Physicians in 1996. He has been made a Life member of the British HIV Association, has helped to write the British HIV Association (BHIVA) anti-viral HIV guidelines and chairs the TB/HIV guidelines committee. He was an advisor on HIV and AIDS to the UK Government Health Select Committee and is on the Expert advisory group on AIDS for the UK Department of Health. He is a DSMB member for the MRC PENTA and DART and NIAID /MRC PENPACT trials. He is an executive member of the European AIDS Clinical Society. He is Vice Chair of the European AIDS trial network (NEAT). He is on the Scientific Advisory Board and Executive Committee of the Charity LEPRa and was a trustee of the Terence Higgins Trust for 6 years (the UK's largest HIV charity). He is co-Chair for the Clinical Science Track for the 2009 IAS conference. He has published widely on clinical aspects of HIV treatment and care.